Folate, Homocysteine, and Adverse Outcomes After Ischemic Stroke
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.124.036527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Mengyao Shi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, MOE Key …. Hauptthemen laut MEDLINE: Homocysteine, Folic Acid, Ischemic Stroke. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
As a risk factor of cardiovascular diseases, homocysteine can be effectively lowered by folate. However, the associations of folate and homocysteine levels with the prognosis of ischemic stroke remained unclear. Methods and Results A total of 3530 patients with ischemic stroke were included. Serum folate and homocysteine levels were measured at admission. The primary outcome was composite of death and major disability (modified Rankin Scale score≥3) at 3 months after stroke onset. Univariate and multivariate logistic regression models were used. The mediation effect of homocysteine was examined. During follow‐up, 1056 participants developed the primary outcome. In the univariate model, participants in the highest quartile of folate had a 29% (95% CI, 0.58–0.87) decreased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with the highest quartile of folate was 0.58 (95% CI, 0.46–0.73) for primary outcome. In contrast, participants in the highest quartile of homocysteine had a 52% (95% CI, 1.24–1.98) increased risk of primary outcome compared with those in the lowest quartile. After multivariate adjustment, the odds ratio associated with highest quartile of homocysteine was 1.57 (95% CI, 1.24–1.98) for primary outcome. In addition, 25.5% of the observed associations between folate and primary outcome was mediated through homocysteine ( P =0.012).
Conclusions
High folate levels were associated with low risks of death and major disability among Chinese patients with ischemic stroke, and homocysteine partially mediated the observed potential beneficial role of folate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College…
- Department of Neurology Minhang Hospital, Fudan University Shanghai China.
- Institute of Science and Technology for Brain Inspired Intelligence Fudan University Shanghai China.
- School of Nursing Suzhou Medical College of Soochow University Suzhou China.
- Institute of Healthy Yangtze River Delta Shanghai Jiao Tong University Shanghai China.
ORCID-Profile: Jin Zheng, Xueyu Mao, Huicong Niu, Yonghong Zhang, Zhengbao Zhu, Jing Zhao
Zitieren
APA
Shi, M., Zheng, J., Liu, Y., Mao, X., Wu, X., Chu, M., Niu, H., Sun, L., Chang, X., He, Y., Liu, Y., Guo, D., Zhang, Y., Zhu, Z., & Zhao, J. (2024). Folate, Homocysteine, and Adverse Outcomes After Ischemic Stroke. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036527
Vancouver
Shi M, Zheng J, Liu Y, Mao X, Wu X, Chu M, et al. Folate, Homocysteine, and Adverse Outcomes After Ischemic Stroke. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.036527
BibTeX
@article{Shi2024,
author = {Shi, Mengyao and Zheng, Jin and Liu, Yang and Mao, Xueyu and Wu, Xuechun and Chu, Min and Niu, Huicong and Sun, Lulu and Chang, Xinyue and He, Yu and Liu, Yi and Guo, Daoxia and Zhang, Yonghong and Zhu, Zhengbao and Zhao, Jing},
title = {Folate, Homocysteine, and Adverse Outcomes After Ischemic Stroke},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.124.036527}
}
EUVIMED